NEW YORK (GenomeWeb) – Sividon Diagnostics of Cologne, Germany, has teamed up with Virchow Laboratories of Shanghai and its sales partner Ready Ruixin to provide its EndoPredict breast cancer relapse prognostic test in China, the company said today.

Sividon's EndoPredict test, launched in 2011, uses cancer gene expression profiling, based on quantitative RT PCR, in combination with standard prognostic factors to assess relapse risk in breast cancer patients and to help decide on the best treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Sponsored by

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.

Sponsored by

About one year ago, the Association for Molecular Pathology (AMP), with liaison representation from the American College of Medical Genetics and Genomics (ACMG), American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP), released a guideline on reporting somatic cancer variants.